dr. plimack on keynote-045 trial for pembrolizumab in urothelial carcinoma
Published 7 years ago • 91 plays • Length 1:18Download video MP4
Download video MP3
Similar videos
-
1:09
dr. plimack on frontline pembrolizumab for urothelial carcinoma
-
1:18
dr. plimack on combo of pembrolizumab/epacodostat in bladder cancer
-
0:57
dr. petrylak on the keynote-045 trial for urothelial carcinoma
-
0:58
significance of keynote-045 trial of pembrolizumab vs chemotherapy in urothelial carcinoma
-
1:45
dr. rosenberg on the keynote-045 trial in advanced urothelial cancer
-
1:19
dr. bellmunt shares keynote-045 data for pembrolizumab versus chemotherapy in bladder cancer
-
1:44
dr. plimack on a phase ib study of pembrolizumab in bladder cancer
-
1:05
dr. petrylak on combinations with pembrolizumab in urothelial carcinoma
-
0:51
impact of the keynote-045 study comparing pembrolizumab and chemotherapy in bladder cancer
-
1:23
how effective is pembrolizumab in cisplatin-ineligible bladder cancer? results from keynote-052
-
0:53
dr. plimack on strategies for developing cure for locally advanced urothelial carcinoma
-
0:47
dr. plimack on the challenges with available immunotherapies for bladder cancer
-
0:49
dr. elizabeth plimack on immunotherapy potential in bladder cancer
-
1:54
two-year follow-up results from keynote-045 study in urothelial carcinoma
-
2:21
dr. galsky on maintenance pembrolizumab in urothelial cancer
-
2:58
dr. bellmunt discusses follow-up data for pembrolizumab vs chemotherapy in bladder cancer
-
1:04
dr. plimack on immunotherapy combinations in bladder cancer
-
3:02
updates from keynote 57: pembrolizumab for patients with bladder cancer
-
1:00
dr. plimack on the growth of immunotherapy in bladder cancer